GlassScriptPhysician profile
Carlos Rosas
NPI 1013929272
$10,507.65
in general payments reported to CMS, 2019-2025
43 companies · $764 in 2025
The $764 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,932 · 2020: $1,179 · 2021: $2,041 · 2022: $1,389 · 2023: $1,187 · 2024: $1,017 · 2025: $764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,968.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,967.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,827.23 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,665.56 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Amarin Pharma, INC. | $1,389.94 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $795.26 | 2019-2025 | Farxiga |
| Merck Sharp & Dohme LLC | $787.72 | 2019-2024 | Verquvo, Steglatro |
| Amgen INC. | $438.34 | 2019-2023 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $424.79 | 2019-2024 | Xarelto |
| Mannkind Corporation | $380.65 | 2019-2023 | Afrezza |
| E.R. Squibb & Sons, L.L.C. | $201.37 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $181.48 | 2019 | |
| Genentech USA, INC. | $179.95 | 2019-2020 | |
| Cardiovascular Systems INC. | $165.30 | 2021 | |
| Sumitomo Pharma America, INC. | $144.78 | 2023-2025 | Orgovyx, Gemtesa |
| Pfizer INC. | $135.67 | 2019-2023 | |
| Madrigal Pharmaceuticals | $134.68 | 2025 | Rezdiffra |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Rosas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.